Efficacy of Protamine Recombinant Human Insulin Mix 40/60 in Treating Elderly Patients with Type 2 Diabetes and Its Impact on Prognosis
Objective:To explore the efficacy of protamine recombinant human insulin mix 40/60(re-ferred to as Gansulin 40/60)in treating elderly patients with type 2 diabetes(T2DM)and its impact on prog-nosis.Methods:A total of 106 elderly T2DM patients admitted to Western Theater General Hospital between December 2022 and December 2023 were randomly divided into a control group(n=53)and a treatment group(n=53).The control group received standard dual antidiabetic therapy(metformin+dapagliflozin),while the treatment group was given Gansulin 40/60 subcutaneous injections.After 12 weeks,efficacy and safety were evaluated,and pre-and post-treatment glycemic indicators,body mass index(BMI),β-cell function,and serum levels of monocyte chemoattractant protein-1(MCP-1),high-sensitivity C-reactive protein(hs-CRP),and interleukin-6(IL-6)were measured.The prognosis of both groups was tracked for 6 months.Results:The overall effective rate in the treatment group was 90.57%,higher than that in the con-trol group(71.70%)(P<0.05).After treatment,the treatment group showed lower fasting plasma glucose(FPG),2-hour postprandial glucose(2hPG),glycosylated hemoglobin(HbA1c),homeostasis model as-sessment of insulin resistance(HOMA-IR),and serum MCP-1,hs-CRP,and IL-6 levels,and higher β-cell function index(HOMA-β)compared to the control group(P<0.05).The overall incidence of adverse reactions in the treatment group(3.77%)was not significantly different from that in the control group(7.55%)(P>0.05).There was no significant difference in the incidence of microvascular complications between the two groups over the 6-month follow-up period(P>0.05).Conclusion:Subcutaneous injection of Gansu-lin 40/60 in elderly T2DM patients is safe and effective,lowering blood glucose levels,promoting β-cell function recovery,and reducing inflammation,though it does not significantly improve short-term prognosis.
Type 2 diabetes mellitusElderlyProtamine recombinant human insulin mixed in-jection 40/60(Ganshulin 40/60)Blood glucoseGlycated hemoglobinPrognosis
万方数据
维普
